Targeting cancer metabolism in the era of precision oncology
One hundred years have passed since Warburg discovered alterations in cancer
metabolism, more than 70 years since Sidney Farber introduced anti-folates that …
metabolism, more than 70 years since Sidney Farber introduced anti-folates that …
Clinical development of metabolic inhibitors for oncology
KM Lemberg, SS Gori, T Tsukamoto… - The Journal of …, 2022 - Am Soc Clin Investig
Metabolic inhibitors have been used in oncology for decades, dating back to antimetabolites
developed in the 1940s. In the past 25 years, there has been increased recognition of …
developed in the 1940s. In the past 25 years, there has been increased recognition of …
[HTML][HTML] Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications
Oxidative phosphorylation (OXPHOS) takes place in mitochondria and is the process
whereby cells use carbon fuels and oxygen to generate ATP. Formerly OXPHOS was …
whereby cells use carbon fuels and oxygen to generate ATP. Formerly OXPHOS was …
The role of imaging biomarkers to guide pharmacological interventions targeting tumor hypoxia
B Gallez - Frontiers in pharmacology, 2022 - frontiersin.org
Hypoxia is a common feature of solid tumors that contributes to angiogenesis, invasiveness,
metastasis, altered metabolism and genomic instability. As hypoxia is a major actor in tumor …
metastasis, altered metabolism and genomic instability. As hypoxia is a major actor in tumor …
NeRD: a multichannel neural network to predict cellular response of drugs by integrating multidimensional data
X Cheng, C Dai, Y Wen, X Wang, X Bo, S He, S Peng - BMC medicine, 2022 - Springer
Background Considering the heterogeneity of tumors, it is a key issue in precision medicine
to predict the drug response of each individual. The accumulation of various types of drug …
to predict the drug response of each individual. The accumulation of various types of drug …
PGC1α/β expression predicts therapeutic response to oxidative phosphorylation inhibition in ovarian cancer
C Ghilardi, C Moreira-Barbosa, L Brunelli, P Ostano… - Cancer Research, 2022 - AACR
Ovarian cancer is the deadliest gynecologic cancer, and novel therapeutic options are
crucial to improve overall survival. Here we provide evidence that impairment of oxidative …
crucial to improve overall survival. Here we provide evidence that impairment of oxidative …
Multiparameter optimization of oxidative phosphorylation inhibitors for the treatment of pancreatic cancer
Targeting oxidative phosphorylation (OXPHOS) complexes is an emerging strategy to
disrupt the metabolism of select cancer subtypes and to overcome resistance to targeted …
disrupt the metabolism of select cancer subtypes and to overcome resistance to targeted …
Combined inhibition of HMGCoA reductase and mitochondrial complex I induces tumor regression of BRAF inhibitor-resistant melanomas
E de Groot, S Varghese, L Tan, B Knighton… - Cancer & …, 2022 - Springer
Background Primary and posttreatment resistance to BRAFV600 mutation–targeting
inhibitors leads to disease relapse in a majority of melanoma patients. In many instances …
inhibitors leads to disease relapse in a majority of melanoma patients. In many instances …
Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities
A Karz, M Dimitrova, K Kleffman… - Pigment cell & …, 2022 - Wiley Online Library
Brain metastases are the most common brain malignancy. This review discusses the studies
presented at the third annual meeting of the Melanoma Research Foundation in the context …
presented at the third annual meeting of the Melanoma Research Foundation in the context …
Aggregation-Induced Emission Photosensitizer Synergizes Photodynamic Therapy and the Inhibition of the NF-κB Signaling Pathway to Overcome Hypoxia in Breast …
J Wang, H Wu, Q Zhao, Y Zou, D Ding… - ACS Applied Materials …, 2022 - ACS Publications
Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast
cancer, and TNBC patients often develop resistance to endocrine or molecular targeted …
cancer, and TNBC patients often develop resistance to endocrine or molecular targeted …